CXCL8 and COVID-19: This latter finding is consistent with evidence by Bronte and colleagues that showed no differences in IL-8 plasma levels of COVID-19 patients treated with baricitinib, despite a significant reduction in IL-1β, IL-6 and TNFα concentrations [48].